JNJ completing correction wave C
NYSE:JNJ
JNJ is in multi decade uptrend peaked at 187 โ presumably end of major wave 5 and turned into Elliott ABC correction, where major wave (A) length is about 37. Per fibo relation major wave (C) should most probably end at 139.5, while intermediate wave โcโ โ a unit of the major wave (C) might break the pattern bringing the end of correction to 133 and beyond until possible exhaustion of the major correction at higher fibo multiples.
At the same time the stock is trading in a downward channel with a lower bound standing now at 141, as well as built-in triangle pattern identifies target as of 137.5 (not very reliable)
Week chart: EMA 50 & 200 confirming death cross โ itโs late coz in JNJ case SMA 50/200 confirmed it earlier at around 160 โ i.e. the stock is already about to be bottomed. RSI in week chart is not yet oversold, while in day chart RSI is heavily oversold.
I would consider weekly and daily RSI to align getting both in oversold territory and open long at somewhere 139-141 with a price target being upper boundary of the current downward channel
4JNJ trade ideas
JNJ Swing Long Conservative Trend Trade 14Conservative Trend Trade 14
+ long impulse
+ support level
+ 1/2 correction
+ T2 level
+ biggest volume 2Sp
+ test
Calculated affordable stop loss
1 to 2 R/R take profit
Daily chart context
+ long impulse
+ 1/2 correction
Monthly chart context
- short impulse
+ biggest volume Sp
+ test
+ 1/2 correction
JNJ Short IdeaThe Dow looks pretty weak right now to me and as we've seen the mag 7 rally relentlessly. I've been avoiding shorts on tech and semis because they are driving the majority of this rally and shorts have not worked. The Dow has been fairly strong, it is near ATH with everything else.
However, there have been a lot of bearish stocks in the Dow such as NKE and DIS, which is where I have focused my shorts recently. I think it may be time for tech to weaken, but it looks like the Dow will as well. NKE and DIS are a bit too low for me to want to short, but I think there's still some good opportunities on stocks like JNJ.
This is a shorter term time frame, but if you zoom out you can see that the ascending trendline shown above, goes back to a major uptrend from 2016. It recently rejected off that trendline and the descending one above. I'd say it's quite bearish to see a break below and rejection of a 10 year trend. I expect downside to continue here for a good while, unless the Dow can hold up and remain strong.
Johnson & Johnson (JNJ) - Approaching the Reversal ZoneIn April, we anticipated a pullback for JNJ, and since then, the stock has dropped approximately 7%, aligning with our expectations. The current trend suggests further downward movement, reinforcing our previous analysis.
We are focusing on the support zone ranging from $134 to $116, with a potential lower bound at $109, the Corona-Low. The ongoing pullback could represent the completion of Wave (4) within this target zone, aligning with multiple levels.
We are going to be monitoring this for signs of a reversal within this zone. This zone will be crucial to confirm the next possible upward movement.
Return of Impulse wave?JNJ has saw strong bullish pressure at the bottom of the downside channel and it is likely to complete a larger degree (ABC) wave. As such, we are ver bullish on NYSE:JNJ
Stochastic OScillator has completed an oversold crossover and longer-term MACD is close to complete an oversold crossover.
Ichimoku Watch: Johnson & Johnson Eyeing Possible Breakout Upcoming Earnings:
Johnson & Johnson (ticker: JNJ) is scheduled to report earnings before the market opens today. The consensus Earnings Per Share (EPS) estimate for the fiscal quarter ending June 2024 is $2.71. The reported EPS for the same quarter last year was $2.80.
Breakout Above Cloud?
The daily chart of Johnson & Johnson shows that this stock has been working with a downtrend since forging an all-time high of $186.69. However, price has struggled to get through $145.00 support since October 2023 and we have recently seen price drive into the upper boundary of the Ichimoku Cloud, made up of the Leading Span B (light orange at $149.30) and the Leading Span A (light green at $147.60). A price break above the upper limit of the Ichimoku Cloud would be considered a bullish signal.
Adding weight to a possible move higher is the Conversion Line (blue at $147.80) crossing above the Base Line (red at $147.50) on 11 July, and price movement trading below its Lagging Span (green at $151.01).
Price Direction?
With the Ichimoku Indicator suggesting a possible breakout higher beyond the Ichimoku Cloud, this could trigger a wave of follow-through buying towards the May top of $154.86.
Johnson & Johnson Downtrend Line Breakout at $148.9 17.07.2024- Johnson & Johnson chart shows a downtrendline breakout at $148.95
- If breakout holds, price could rally to $152.00; if $152.00 is breached, target $154.40.
- If breakout fails, price may drop to $145.06; if $145.06 is breached, target $140.12.
Apply risk management
Risk Warning: Trading in CFDs is highly speculative and carries a high level of risk. It is possible to lose all of your invested capital. These products may not be suitable for everyone, and you should ensure that you fully understand the risks taking into consideration your investment objectives, level of experience, personal circumstances as well as personal resources. Speculate only with funds that you can afford to lose. Seek independent advice if necessary. Please refer to our Risk Disclosure.
BDSwiss is a trading name of BDS Markets and BDS Ltd.
BDS Markets is a company incorporated under the laws of the Republic of Mauritius and is authorized and regulated by the Financial Services Commission of Mauritius ( FSC ) under license number C116016172, address: 6th Floor, Tower 1, Nexteracom Building 72201 Ebene.
BDS Ltd is authorized and regulated by the Financial Services Authority Seychelles (FSA) under license number SD047, address: Suite 3, Global Village, Jivanโs Complex, Mont Fleuri, Mahe, Seychelles. Payment transactions are managed by BDS Markets (Registration number: 143350)
Disclaimer
Johnson & Johnson - JNJ - Buy it! - longDear traders,
Id like to share this idea in order to take long positions, basically the price looking for a support level around 150$ (psicological level).
140- 150$ is is a good price range to look for buying opportunities.
General trend is still uptrend althouth it has been in a retracement for the last months which is good for capturing buying opportunities
best,
JNJ impending shortThe chart illustrates the possibility of a correction down to a major trend line. This would mean millions of dollars lost in market cap within the next several months or years. If the movement is drastic we may see the company attempt perform countermeasures to provide shareholders a soft landing. One of these countermeasures could be (which I think will be more than likely) layoffs, or termination of complete organizations within the company. As technology advances and consumers of JNJ products increase in cost, the company may pivot to less expensive methods of operations. Attrition is a key variable that I foresee in the near future which could help the company regain some stability in the market. Many people will lose their jobs, but shareholder interest is at the forefront of any good company. Skills are easy to obtain nowadays but public moral is probably at an all time low or leveled with 1950s Vietnam era. If people are unmotivated to learn, they will contribute to the overall downturn of the economy.
J&J Entangled in Talc-Related Lawsuits and Bankruptcy AllegationCore Issues:
* J&J faces numerous lawsuits alleging its talc products contain asbestos and cause cancer.
* The company's utilization of a "Texas two-step" bankruptcy strategy to shield assets from litigation has drawn accusations of fraud.
Recent Developments:
* Cancer victims filed a class action lawsuit on May 22nd, 2024, alleging J&J's fraudulent use of bankruptcy and asset transfers to avoid compensation.
* J&J maintains the safety of its talc and claims the lawsuit disrupts their proposed settlement plan.
Broader Implications:
* This legal battle raises concerns about potential abuses of bankruptcy laws by corporations seeking to evade product liability.
* The case has significant financial ramifications for J&J, with analysts citing negative impacts on stock valuation.
Conclusion:
* The outcome of these lawsuits will determine compensation for victims, J&J's future financial liabilities, and potentially set precedents for corporate responses to mass tort claims.
* Upcoming developments, such as the claimant's vote on the settlement and the court's response to the latest bankruptcy filing, will be crucial in resolving this protracted dispute.
JNJ Johnson & Johnson Options Ahead of EarningsIf you haven`t bought JNJ before the previous earnings:
Then analyzing the options chain and the chart patterns of JNJ Johnson & Johnson prior to the earnings report this week,
I would consider purchasing the 145usd strike price Puts with
an expiration date of 2025-1-17,
for a premium of approximately $7.55.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
Johnson & Johnson's Q1 Triumph: Surpassing ExpectationsJohnson & Johnson (NYSE: NYSE:JNJ ) has kicked off 2024 with a resounding victory, showcasing robust first-quarter earnings that outpaced Wall Street estimates and signaling a promising trajectory for the rest of the year.
The pharmaceutical giant reported an impressive adjusted EPS of $2.71, marking a remarkable 12.4% surge compared to the previous year. This stellar performance surpassed analysts' projections of $2.64, underscoring the company's resilience and strategic prowess.
In terms of revenue, Johnson & Johnson ( NYSE:JNJ ) posted sales of $21.38 billion, reflecting a steady 2.3% increase year over year. While this figure nearly mirrored market expectations, the operational growth of 3.9% and adjusted operational growth of 4.0% underscored the company's underlying strength and adaptability in navigating market dynamics.
One of the standout performers in Johnson & Johnson's portfolio was its Innovative Medicine segment, which witnessed robust operational sales growth of 8.3% to reach $13.6 billion. Notably, sales of key drugs such as Stelara and Darzalex demonstrated resilience, with the latter experiencing a notable 19% surge in revenue.
Moreover, the company's medical devices business proved to be a significant driver of growth, generating sales of $7.82 billion during the quarter, marking a commendable 4.5% year-over-year increase. This uptick was fueled by strong performances in electrophysiology products and cardiovascular solutions, showcasing Johnson & Johnson's ( NYSE:JNJ ) diverse revenue streams and market leadership in healthcare innovation.
In a move sure to delight investors, Johnson & Johnson ( NYSE:JNJ ) announced a 4.2% increase in its quarterly dividend, a testament to its commitment to delivering value to shareholders amidst a challenging economic landscape.
Looking ahead, Johnson & Johnson ( NYSE:JNJ ) raised its fiscal year 2024 guidance, projecting operational sales in the range of $88.7 billion to $89.1 billion and adjusted EPS between $10.57 and $10.72. This optimistic outlook, coupled with the company's track record of delivering on its promises, instills confidence in its ability to navigate future opportunities and challenges.
Despite a slight dip in premarket trading following the earnings release, Johnson & Johnson's ( NYSE:JNJ ) strong performance in Q1 sets a solid foundation for continued success, reaffirming its position as a leader in the healthcare industry and a reliable investment choice for shareholders worldwide.
JOHNSON & JOHNSON Time to start buying.Johnson & Johnson (JNJ) quickly hit the $147.00 Target that we set on our very recent sell call (April 03, see chart below) and is now approaching the bottom of the massive 2-year Channel Down:
Even though based on the very reliable and consistent Sine Waves, the bottom might be a process that can take up to 2-months, the stock is low enough for medium-term investors to start considering adding buys.
On top of that, the 1D RSI is highly oversold below 20.00, the lowest it has been in more than 4 years (since February 28 2020)! As a result and since the Bearish Legs of this Channel Down have ranged within -14.78% and -17.58%, we are turning bullish on this stock, targeting $157.50 (minimum +13.00% rise as with January 22 2024 High).
-------------------------------------------------------------------------------
** Please LIKE ๐, FOLLOW โ
, SHARE ๐ and COMMENT โ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. **
-------------------------------------------------------------------------------
๐ธ๐ธ๐ธ๐ธ๐ธ๐ธ
๐ ๐ ๐ ๐ ๐ ๐
Johnson & Johnson (JNJ): Navigating a Constricted MarketExecutive Summary:
The investment landscape for Johnson & Johnson (JNJ) appears fraught with challenges, as technical indicators on the monthly chart convey a narrative of heightened caution. A synthesis of volume data, oscillator behavior, and cloud-based resistance delineates a precarious pathway for the equity. Amid the backdrop of an imminent earnings report, our technical scrutiny attempts to extrapolate JNJ's potential market trajectory with speculative price targets, enriching the strategic arsenal of the discerning investor.
Technical Examination:
JNJ's price action is ensconced within a pivotal junction, as evidenced by the candlesticks' interaction with the Ichimoku Cloud and the Fibonacci retracement levels. The recent close below the 0.618 Fib level (171.75) undermines bullish fortitude, while the cloudโs senkou span A (160.46) looms overhead as a formidable deterrent to upward mobility.
Ichimoku Cloud Analysis:
The cloud's forward projection signals a redoubtable resistance zone, with senkou span B (165.82) reinforcing the ceiling. The Tenkan-sen (147.60) beneath the Kijun-sen (163.14) augurs for continued caution, as the lagging span flirts with price candles from 26 periods prior, suggesting latent bearish sentiment.
Relative Strength Index (RSI):
JNJ's RSI presents a demure posture at 41.88, a liminal state neither entrenched in bullish territory nor capitulating to bearish dominion. Such neutrality belies the latent potential for a decisive move, contingent upon catalysts from the forthcoming earnings discourse.
Moving Average Convergence Divergence (MACD):
The MACD chronicles a tale of bearish momentum, as the MACD line (-1.21) diverges from the signal line (-2.32), albeit with diminishing bearish histogram bars. This could intimate a forthcoming attenuation of downward pressure or a pause in bearish continuation.
On-Balance Volume (OBV):
The OBV metric at 9.318B exhibits a steady trend, lacking significant impetus. This volume-based indicator's plateau suggests a market in equilibrium, with neither buyers nor sellers achieving a clear victory in volume dominance.
Market Context and Speculative Price Forecasts:
The strategic positioning of JNJ ahead of its earnings report is akin to a game of high-stakes poker. With an average volume (30D) of 6.75M and a market capitalization of $356.5B, JNJโs beta of 0.54 insinuates lower volatility relative to the broader market. Dividend yield at 3.20% continues to be a linchpin for yield-seeking investors.
Given the confluence of technicals, a breach below the current Tenkan-sen level could cascade into a test of the 145.00 USD support echelon, with a speculative target near the 140.00 USD fulcrum if bearish sentiment crystallizes post-earnings. Conversely, should the earnings report provide a catalyst for a bullish reversal, an assault on the 150.00 USD level may ensue, with the cloud's senkou span acting as the next battleground for bulls.
Closing Thoughts:
In the looming shadow of JNJ's earnings report, the amalgamation of technical signals leans towards a bearish bias, tempered by the potential for a shift in sentiment. Market participants would do well to monitor volume flows and price action post-earnings, with a tactical eye on the RSI and MACD for early indications of momentum shifts. Investors are reminded that technical analysis is not infallible and must be integrated with a robust risk management strategy.
Disclaimer:
This technical analysis is for informational purposes only and does not constitute investment advice. Traders and investors should perform their own due diligence and consider their risk tolerance before engaging in the market. Past performance is not indicative of future returns, and the speculative nature of price targets should be approached with caution.